相关实验视频
Updated: May 21, 2025

04:39
Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
Published on: March 17, 2023
1.5K
K-Means 聚类揭示了Graves 疾病中的长期甲状腺素受体抗体模式:10年研究的见解,对Graves 轨道病的影响
Jungyul Park1, Jae Hyun Kim2, Hee-Young Choi2
1Department of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Journal of clinical medicine
|March 17, 2025
概括
这项研究确定了四种甲状腺刺激激素受体抗体 (TRAb) 模式在Graves病 (GD). 基线TRAb水平和性别预测正常化,对于量身定制的GD治疗至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 医学统计 医学统计
背景情况:
- 格雷夫斯病 (GD) 是一种自身免疫性疾病,其特征是甲状腺刺激激素受体抗体 (TRAb) 的升高.
- 了解长期TRAb轨迹和正常化因素对于管理GD及其相关并发症,如Graves轨道病 (GO) 至关重要.
研究的目的:
- 探索GD患者的长期TRAb水平变化.
- 为了确定TRAb正常化的预测因素.
- 为了调查TRAb轨迹和GO共发病之间的相关性.
主要方法:
- 对403名GD患者的回顾性分析,初始TRAb≥1.5 IU/L,监测至少3年.
- K-意味着集群来定义不同的TRAb变化模式 (A-D).
- 基于考克斯回归的时间对事件分析,使用"生存率"来评估正常化率,考虑年龄,性别,初始TRAb和GO.
主要成果:
- 确定了四种不同的TRAb模式 (A-D),基线水平和GD持续时间各不相同.
- 模式A显示了最高的正常化率 (96%),而模式B,C和D的正常化率较低 (分别为80%,29%,13%).
- 在女性和基线TRAb<6.14 IU/L的女性中观察到更高的正常化"生存率";水平≥6.14 IU/L经常持续超过十年. 在不同模式中,GO并发症并没有显著差异.
结论:
- 在GD患者中,K-means集群确定了四种独特的TRAb模式.
- 基线TRAb水平 (中位数6.14IU/L) 和女性性别是TRAb正常化的显著预测因素.
- 早期的TRAb监测和个性化治疗策略至关重要,特别是对于持续升高TRAb水平的患者.
相关概念视频
Synthesis and Regulation of Thyroid Hormones
4.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.1K
Myasthenia Gravis: Diagnostic Tests
585
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
585
Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K

